TORRENT PHARMA Share Price Up by 5%; BSE HEALTHCARE Index Up 3.1%
February 3, 2021 12:33 PM

TORRENT PHARMA share price has zoomed 5% and is presently trading at Rs 2,710.

Meanwhile, the BSE HEALTHCARE Index is at 21,756 (up 3.1%).

Among the top Gainers in the BSE HEALTHCARE Index today are TORRENT PHARMA (up 5.0%) and JUBILANT LIFE SCIENCES (up 8.2%).

ALEMBIC PHARMA (down 0.7%) and J.B.CHEMICALS (down 0.9%) are among the top losers today.

Over the last one year, TORRENT PHARMA has moved up from Rs 1,906 to Rs 2,710, registering a gain of Rs 804 (up 41.7%).

On the other hand, the BSE HEALTHCARE has moved up from 13,734 to 21,756, registering a gain of 8,022 points (up 58.2%) during the last 12 months.

The top buzzing stocks among the BSE HEALTHCARE Index stocks during this same period were LAURUS LABS (up 310.8%), GRANULES INDIA (up 147.9%) and STRIDES PHARMA SCIENCE (up 105.1%).

What About the Benchmark Indices?

The BSE Sensex is at 50,408 (up 1.2%).

The top gainers among the BSE Sensex stocks today are INDUSIND BANK (up 8.1%), SUN PHARMA (up 5.5%) and POWER GRID (up 5.5%). Other gainers include M&M (up 4.4%) and TECH MAHINDRA (up 4.0%). The most traded stocks in the BSE Sensex are SBI and ICICI BANK.

In the meantime, NSE Nifty is at 14,840 (up 1.2%). The top gainers in the NSE Nifty include INDUSIND BANK (up 7.7%), POWER GRID (up 5.6%) and SUN PHARMA (up 5.6%). Other gainers include CIPLA (up 5.3%) and DR. REDDYS LAB (up 4.7%) are among the top gainers in NSE Nifty.

Over the last 12 months, the BSE Sensex has moved up from 39,736 to 50,408, registering a gain of 10,672 points (up 26.77%).

TORRENT PHARMA Financial Update...

TORRENT PHARMA net profit stood at Rs 3 billion for the quarter ended September 2020, compared to a profit of Rs 3 billion a year ago. Net Sales rose 2.6% to Rs 20.2 billion during the period as against Rs 19.7 billion in July-September 2019.

For the year ended March 2019, TORRENT PHARMA reported 17.0% increase in net profit to Rs 7.9 billion compared to net profit of Rs 6.8 billion during FY18.

Revenue of the company grew 29.0% to Rs 77 billion during FY19.

The current Price to earnings ratio of TORRENT PHARMA, based on rolling 12 month earnings, stands at 38.2x.